Collaboration, License and Research Agreements (Tables) |
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Collaboration License And Research Agreements [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Reconciliation of Deferred Revenue | A reconciliation of the closing balance of deferred revenue related to the BMS Collaboration Agreement and the Lilly Agreement, for the six months ended June 30, 2026 and 2025 is as follows (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||